There is also a good biological rationale for combining immunotherapy with locoregional treatment, as embolisation can induce tumour necrosis and enhance tumour antigen presentation.[86], [87], [88] There are several ongoing studies investigating whether clinical outcomes with locoregional therapy can be improved upon by combining with immunotherapy, either as a monotherapy (NCT04268888, NCT04340193) or in combination with anti-VEGF(R)-directed therapy including bevacizumab, lenvatinib and regorafenib (NCT04712643, NCT04340193, NCT04246177). Here, VEGFA is linked to neoplasm.